VKTX is up +27.53% to $38.40, surging in premarket trading and extending gains into the regular session after a positive VK2735 readout. The primary catalyst: top-line results from the VK2735 maintenance study showed patients retained up to 97% of weight loss on every-other-week dosing and up to 90% on monthly dosing, versus 61% for placebo.

CAI shares advanced roughly 16.7% over the last 30 days, from about $26.27 to $30.65, extending a broader multi-month rally. The move reflects follow-through from record second-quarter 2026 results, including 45% year-over-year revenue growth and a raised full-year outlook.

TLX fell -9.85% to about $11.35 during Monday's regular session, down from a prior close of $12.59. The drop followed Telix's $1.65 billion upfront merger agreement with privately held German radioisotope producer ITM Isotope Technologies Munich.

PBLS fell -11.84% to $36.79 during regular trading Monday, down from Friday's $41.73 close. The drop came amid a broad biotech and pharmaceutical selloff, with PBLS among the session's biggest sector losers.

BRVE is down -14.32% to $25.02 during Monday's regular session, off Friday's $29.20 close, on heavy volume (~1.0M shares vs ~464K average). The slide extends a post-earnings selloff after Sept 8 Q2 results showed a far wider loss (diluted EPS -$2.51 vs -$0.25 consensus) with zero revenue.

APMD fell -12.66% during regular trading, retreating to roughly $25.33 from Friday's $29.00 close. The decline follows Friday's +3.17% surge on ~3.1M shares—well above its ~531K average—leaving the newly public biotech prone to profit-taking.

CUE is down -27.45% in the regular session, trading near $26.88 versus Friday's close of $37.05. The stock initially spiked roughly +41% premarket after positive Phase 2 CUE-221 results in chronic spontaneous urticaria (primary and key secondary endpoints met).

Twist Bioscience (TWST) rose roughly 15% over the trailing 30 days, climbing from about $145 in late August to $166.99 at the September 18 close. The rally accelerated after Twist announced a data-services agreement with Eli Lilly's ( LLY ) AI-driven TuneLab platform, sending shares up more than 31% in a single week.

Avidity Biosciences (RNA) shares fell approximately 34.7% over the trailing 30 days, declining from a closing price of $13.71 on August 19, 2026, to $8.95 on September 18, 2026. The move was driven primarily by a September 8 setback for del-desiran, the lead antibody-oligonucleotide conjugate (AOC) candidate built on Avidity's platform, which missed its primary endpoint in the Phase III HARBOR study for myotonic dystrophy type 1 (DM1).

PRAX fell roughly 20% over the last 30 days, sliding from $375.94 on August 21 to $298.95 at the September 18 close. The pullback followed a sharp rally triggered by second-quarter 2026 results, reflecting profit-taking after the stock touched an intraday peak above $390 in mid-August.

Arrowhead Pharmaceuticals (ARWR) fell about 25.65% over the trailing 30 days, from a close of $89.41 to $66.48, despite a steady stream of positive clinical updates. The decline followed a powerful rally, with the stock still up more than 110% over the trailing 12 months, underscoring profit-taking and fading short-term momentum.

XENE is trading down roughly -28.7% to $40.89 versus the prior session close of $57.35. The drop unfolded after-hours Thursday and extended into Friday's premarket, after the stock had closed the regular session up +1.04% at $57.35.

XRTX is up +15.66% in early regular-session trading, rising to roughly $1.92 from a prior close of $1.66. The move followed the company's announcement that it plans to submit an IND for its XRx-026 gout program to the FDA in Q4 2026.

Dyne Therapeutics shares declined about 30.5% over the 30 days through mid-September 2026, falling from roughly $26.00 to approximately $18.06. The selloff was triggered by Novartis reporting that its Phase 3 HARBOR study of del-desiran failed its primary endpoint in myotonic dystrophy type 1 (DM1), raising read-through concerns for Dyne's competing z-basivarsen program.

INO gained +7.83% during regular trading hours, rising to $1.24 from a prior-session close of $1.15. The advance reverses a weeklong slide that took shares from $1.28 down to $1.15, suggesting a technical rebound in a volatile small-cap biotech.

TPST is down roughly -25.6% to about $0.90 in Thursday's regular session, giving back a large portion of the previous session's gain. On Wednesday the stock closed up +60.18% at $1.21 (intraday high $1.48) after Tempest announced an exclusive option to license Senlang's CD7-targeted lentiviral in vivo CAR-T platform, including a BCMA/GPRC5D Phase 1 candidate.

LGVN plunged about -56% to roughly $2.94 from a prior close of $6.68, with the move hitting during the after-hours session following a trading halt. The primary catalyst: the Phase 2b ELPIS II trial of cell therapy laromestrocel in hypoplastic left heart syndrome missed its primary endpoint of change in right ventricular ejection fraction at Month 12 (p=0.8336).

MNOV jumped +29.76% to $3.27 during regular trading, up from a $2.52 prior-session close. The primary catalyst was Roth/MKM initiating coverage with a Buy rating and a $6.00 price target, citing ibudilast's (MN-166) potential in ALS.

MRNA is up +9.88% to roughly $160 during the regular session, versus a prior close of $145.62. Primary catalyst: positive Phase 3 results for the personalized mRNA cancer vaccine intismeran autogene, used with Merck's Keytruda, in high-risk melanoma — the first late-stage mRNA oncology success.

ALMS fell -6.07% to about $7.89 during regular trading, extending the prior session's slide. The move follows the Phase 2b LUMUS lupus trial readout, which missed its primary and secondary endpoints in the broader SLE population.